| [1] Walboomers J M, Jacobs M V, Manos M M, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. The Journal of Pathology, 1999, 189(1): 12-19.
[2] Pisani P, Bray F, Parkin D M. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. International Journal of Cancer Journal International du Cancer, 2002, 97(1): 72-81.
[3] Zhang W, Jiang Y, Yu Q, et al. EGFR promoter methylation, EGFR mutation, and HPV infection in Chinese cervical squamous cell carcinoma. Applied immunohistochemistry & molecular morphology : AIMM/official publication of the Society for Applied Immunohistochemistry, 2015,in pvess.
[4] Bartel D P. MicroRNAs: target recognition and regulatory functions. Cell, 2009, 136(2): 215-233.
[5] Kusenda B, Mraz M, Mayer J, et al. MicroRNA biogenesis, functionality and cancer relevance. Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 2006, 150(2): 205-215.
[6] Zhang B H, Pan X P, Cobb G P, et al. microRNAs as oncogenes and tumor suppressors. Dev Biol, 2007, 302(1): 1-12.
[7] Lee J W, Choi C H, Choi J J, et al. Altered MicroRNA expression in cervical carcinomas. Clinical Cancer Research, 2008, 14(9): 2535-2542.
[8] Wang X H, Tang S, Le S Y, et al. Aberrant expression of oncogenic and tumor-suppressive MicroRNAs in cervical cancer is required for cancer cell growth. PLoS One, 2008, 3(7): 11.
[9] Shen S N, Wang L F, Jia Y F, et al. Upregulation of microRNA-224 is associated with aggressive progression and poor prognosis in human cervical cance. Diagn Pathol, 2013, 8(69).
[10] Li Y, Wang F, Xu J, et al. Progressive miRNA expression profiles in cervical carcinogenesis and identification of HPV-related target genes for miR-29. The Journal of Pathology, 2011, 224(4): 484-495.
[11] Wilting S M, Van Boerdonk R A, Henken F E, et al. Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Molecular Cancer, 2010, 9(167).
[12] Tian Q F, Li Y, Wang F F, et al. MicroRNA detection in cervical exfoliated cells as a triage for human papillomavirus-positive women. JNCI-J Natl Cancer Inst, 2014, 106(9): 8.
[13] Peng X H, Huang H R, Lu J, et al. MiR-124 suppresses tumor growth and metastasis by targeting Foxq1 in nasopharyngeal carcinoma. Molecular Cancer, 2014, 13(186).
[14] Hu C B, Li Q L, Hu J F, et al. miR-124 inhibits growth and invasion of gastric cancer by targeting ROCK1. Asian Pacific Journal of Cancer Prevention : APJCP, 2014, 15(16): 6543-6546.
[15] Shi X B, Xue L, Ma A H, et al. Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells. Oncogene, 2013, 32(35): 4130-4138.
[16] Sun Y, Ai X, Shen S, et al. NF-kappaB-mediated miR-124 suppresses metastasis of non-small-cell lung cancer by targeting MYO10. Oncotarget, 2015, 6(10):8244-8254.
[17] Zhang Y, Zheng L, Huang J, et al. MiR-124 Radiosensitizes human colorectal cancer cells by targeting PRRX1. PLoS One, 2014, 9(4): e93917.
[18] Hooper J D, Zijlstra A, Aimes R T, et al. Subtractive immunization using highly metastatic human tumor cells identifies SIMA135/CDCP1, a 135 kDa cell surface phosphorylated glycoprotein antigen. Oncogene, 2003, 22(12): 1783-1794.
[19] Yang L, Nyalwidhe J O, Guo S, et al. Targeted identification of metastasis-associated cell-surface sialoglycoproteins in prostate cancer. Molecular & Cellular Proteomic, 2011, 10(6): M110.007294.
[20] Miyazawa Y, Uekita T, Hiraoka N, et al. CUB domain-containing protein 1, a prognostic factor for human pancreatic cancers, promotes cell migration and extracellular matrix degradation. Cancer Research, 2010, 70(12): 5136-5146.
[21] Scherl-Mostageer M, Sommergruber W, Abseher R, et al. Identification of a novel gene, CDCP1, overexpressed in human colorectal cancer. Oncogene, 2001, 20(32): 4402-4408.
[22] Perry S E, Robinson P, Melcher A, et al. Expression of the CUB domain containing protein 1 (CDCP1) gene in colorectal tumour cells. FEBS Letters, 2007, 581(6): 1137-1142.
[23] Uekita T, Tanaka M, Takigahira M, et al. CUB-domain-containing protein 1 regulates peritoneal dissemination of gastric scirrhous carcinoma. The American Journal of Pathology, 2008, 172(6): 1729-1739.
[24] Ikeda J, Oda T, Inoue M, et al. Expression of CUB domain containing protein (CDCP1) is correlated with prognosis and survival of patients with adenocarcinoma of lung. Cancer Science, 2009, 100(3): 429-433.
[25] Awakura Y, Nakamura E, Takahashi T, et al. Microarray-based identification of CUB-domain containing protein 1 as a potential prognostic marker in conventional renal cell carcinoma. Journal of Cancer Research and Clinical Oncology, 2008, 134(12): 1363-1369.
[26] Bhatt A S, Erdjument-Bromage H, Tempst P, et al. Adhesion signaling by a novel mitotic substrate of src kinases. Oncogene, 2005, 24(34): 5333-5343.
[27] Benes C H, Poulogiannis G, Cantley L C, et al. The SRC-associated protein CUB Domain-containing protein-1 regulates adhesion and motility. Oncogene, 2012, 31(5): 653-663. |
